


New horizons in the era of precision medicine in lung cancer: **KRAS** and **DLL3** as emerging treatment targets



AMGEN-sponsored virtual symposium: Agenda

Welcome and introduction

Luis Paz-Ares (Madrid, Spain)

5 min

Emerging biomarkers in NSCLC and SCLC

Keith Kerr (Aberdeen, UK)

25 min presentation

KRAS^{G12C} mutant NSCLC: Current and emerging treatments

Jürgen Wolf (Cologne, Germany)

25 min presentation

BiTE – A new way of targeting DLL3 in SCLC

Luis Paz-Ares (Madrid, Spain)

25 min presentation

Future perspectives

All

10 min

Available on demand from
Tuesday 22nd September 2020, 09:00 CET